Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873038 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
A Phase 1 study of Kidney Failure, Chronic and Renal Dialysis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 3
- Study locations
NCT03873038: Completed Phase 1 study of Kidney Failure, Chronic and Renal Dialysis, sponsored by Merck Sharp & Dohme.
NCT03873038 is a Phase 1 study of Kidney Failure, Chronic and Renal Dialysis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 38 participants, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03873038, a Phase 1 study of Kidney Failure, Chronic and Renal Dialysis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants that experienced an AE was summarized.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MK-2060
Study Locations (3)
Florida
- Orlando Clinical Research Center ( Site 0002) - Orlando
Minnesota
- Prism Research ( Site 0003) - Saint Paul
Tennessee
- New Orleans Center for Clinical Research ( Site 0001) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2021-12-20 |
| Phase | Phase 1 |
What the finished NCT03873038 record still lists
NCT03873038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03873038 reports a single indexed study location in Florida, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03873038 about?
NCT03873038 is a clinical study titled "Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).
What is the current status of trial NCT03873038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2019-04-29. Estimated completion is 2021-12-20.
What conditions does trial NCT03873038 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, Renal Dialysis.
What interventions are being tested in trial NCT03873038?
The interventions under investigation include: Placebo (DRUG), MK-2060 (DRUG).
Who is sponsoring clinical trial NCT03873038?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03873038 being conducted?
This trial has 3 study locations across Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03873038's enrollment target sits among peer trials
38 15th of 23 higher than 9 of 23 other Kidney Failure, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Failure, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
COMPLETED · Phase 1
-
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI